The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
Why the study?
Does ticagrelor reduce adverse clinical outcomes compared to clopidogrel similarly in men and women with acute coronary syndromes?
Population
Patients with ST-elevation or non-ST-elevation acute coronary syndromes participating in the PLATelet…
Comparison
Ticagrelor vs Clopidogrel
Design
RCT, Randomized
Authors
Discussion
Loading...
Member takes
Implication
Supports ticagrelor over clopidogrel in ACS regardless of sex; confirms consistent efficacy without sex interaction in this RCT.
Structured PICO
Does ticagrelor reduce adverse clinical outcomes compared to clopidogrel similarly in men and women with acute coronary syndromes?
P
Population
Patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) participating in the PLATelet inhibition and patient Outcomes (PLATO) trial
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel
O
Outcome
Primary composite outcomescomposite
Ticagrelor demonstrates similar efficacy and safety profiles in both men and women with acute coronary syndromes compared to clopidogrel.
Cite This Study
Husted et al. (2014) studied this question.